Medical Editor: John P. Cunha, DO, FACOEP
What Is Eucrisa?
Eucrisa (crisaborole) ointment, 2%, for topical use is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.
What Are Side Effects of Eucrisa?
Common side effects of Eucrisa include application site pain.
Dosage for Eucrisa
Apply a thin layer dose of Eucrisa twice daily to affected areas.
What Drugs, Substances, or Supplements Interact with Eucrisa?
Eucrisa may interact with other drugs. Tell your doctor all medications and supplements you use.
Eucrisa During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Eucrisa; it is unknown if it would affect a fetus. It is unknown if Eucrisa passes into breast milk or how it will affect a nursing infant. Consult your doctor before breastfeeding.
Additional Information
Our Eucrisa (crisaborole) ointment, 2%, for topical use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
SLIDESHOW
Rosacea, Acne, Shingles, Covid-19 Rashes: Common Adult Skin Diseases See Slideshow3 pharmacies near 20147 have coupons for Eucrisa (Brand Names:Eucrisa Ointment for 60GM of 2%)
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two double-blind, vehicle-controlled clinical trials (Trial 1 and Trial 2), 1012 subjects 2 to 79 years of age with mild to moderate atopic dermatitis were treated with EUCRISA twice daily for 4 weeks. The adverse reaction reported by ≥1% of EUCRISA-treated subjects is listed in Table 1.
Table 1: Adverse Reaction Occurring in ≥1% of Subjects in Atopic Dermatitis Trials through Week 4
| Adverse Reaction | EUCRISA N=1012 n (%) | Vehicle N=499 n (%) |
| Application site paina | 45 (4) | 6 (1) |
| a Refers to skin sensations such as burning or stinging. | ||
Less common (<1%) adverse reactions in subjects treated with EUCRISA included contact urticaria [see WARNINGS AND PRECAUTIONS].
Postmarketing Experience
The following adverse reactions have been identified during postapproval use of EUCRISA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:
Skin and Subcutaneous: allergic contact dermatitis.
Read the entire FDA prescribing information for Eucrisa (crisaborole)
